Vertex Pharmaceuticals Stock Today

VRTX Stock  USD 450.97  0.60  0.13%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 1

 
High
 
Low
Very Small
Vertex Pharmaceuticals is trading at 450.97 as of the 24th of November 2024; that is 0.13 percent increase since the beginning of the trading day. The stock's open price was 450.37. Vertex Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Vertex Pharmaceuticals's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of July 1991
Category
Healthcare
Classification
Health Care
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 257.53 M outstanding shares of which 4.5 M shares are at this time shorted by private and institutional investors with about 4.51 trading days to cover. More on Vertex Pharmaceuticals

Vertex Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President CEOMD FASN
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP 500 Index, Nasdaq 100, NASDAQ 100 Pre, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, Dow Jones Biotechnology, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.250.4342
Way Down
Very volatile
Gross Profit Margin1.090.8721
Fairly Up
Slightly volatile
Total Current Liabilities3.7 B3.5 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total1.7 B1.6 B
Sufficiently Up
Slightly volatile
Total Assets23.9 B22.7 B
Sufficiently Up
Slightly volatile
Total Current Assets14.9 B14.1 B
Sufficiently Up
Slightly volatile
Debt Levels
Vertex Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vertex Pharmaceuticals' financial leverage. It provides some insight into what part of Vertex Pharmaceuticals' total assets is financed by creditors.
Liquidity
Vertex Pharmaceuticals currently holds 808.4 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 4.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

End Period Cash Flow

10.89 Billion
Vertex Pharmaceuticals (VRTX) is traded on NASDAQ Exchange in USA. It is located in 50 Northern Avenue, Boston, MA, United States, 02210 and employs 5,400 people. Vertex Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 116.14 B. Vertex Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 257.53 M outstanding shares of which 4.5 M shares are at this time shorted by private and institutional investors with about 4.51 trading days to cover. Vertex Pharmaceuticals currently holds about 9.77 B in cash with 3.54 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Vertex Pharmaceuticals shows a total of 257.53 Million outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Vertex Pharmaceuticals's common stock.
Check Vertex Ownership Details

Vertex Stock Institutional Holders

InstituionRecorded OnShares
Wellington Management Company Llp2024-06-30
4.1 M
Amundi2024-06-30
3.5 M
Norges Bank2024-06-30
3.4 M
Loomis, Sayles & Company Lp2024-06-30
3.1 M
Massachusetts Financial Services Company2024-09-30
2.9 M
Bank Of America Corp2024-06-30
2.6 M
Ubs Asset Mgmt Americas Inc2024-09-30
2.4 M
Legal & General Group Plc2024-06-30
2.4 M
Hhg Plc2024-06-30
2.4 M
Capital World Investors2024-09-30
26.8 M
Vanguard Group Inc2024-09-30
23.2 M
View Vertex Pharmaceuticals Diagnostics

Vertex Pharmaceuticals Historical Income Statement

At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024. View More Fundamentals

Vertex Stock Against Markets

Vertex Pharmaceuticals Corporate Management

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.